Arix Bioscience plc announced changes to the Company's investment team. Jonathan Tobin, PhD, currently Investment Director at Arix in London, is appointed Managing Director effective immediately. Jonathan will also join the boards of Arix portfolio companies VelosBio and Depixus, in addition to his current board positions at Artios Pharma, Atox Bio, STipe Therapeutics and Quench Bio. Other changes to the investment team include: John Cassidy currently Investment Associate at Arix in London, has been promoted to Principal; Christian Schetter, PhD, Entrepreneur in Residence (EIR), will join the board of Aura Biosciences and Tim Xu, MD, Investment Associate, will join the board of OptiKira and assume the role of Board Observer at Amplyx Pharmaceuticals. Roberto Iacone, MD, who recently joined as EiR jointly sponsored by Takeda, will remain based in Switzerland.